Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0MT0M
|
|||
| Former ID |
DAP000236
|
|||
| Drug Name |
Apraclonidine
|
|||
| Synonyms |
Aplonidine; Apraclonidina; Apraclonidinum; Iopidine; Iopidine Eye; ALO 2145; Apraclonidina [INN-Spanish]; Apraclonidine (INN); Apraclonidine [INN:BAN]; Apraclonidinum [INN-Latin]; Iopidine (TN); P-aminoclonidine; Para-aminoclonidine; 2,6-dichloro-1-N-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine; 2,6-dichloro-N(1)-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine; 2-(4-Amino-2,6-dichloroanilino)-2-imidazoline hydrochloride; 2-(4-amino-2,6-dichloro)phenyliminoimidazolidine; 4-Aminoclonidine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Intra ocular pressure reduction [ICD-11: 9C40; ICD-10: H47.0] | Approved | [1], [2] | |
| Therapeutic Class |
Antiglaucomic Agents
|
|||
| Company |
Alcon Canada Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C9H10Cl2N4
|
|||
| Canonical SMILES |
C1CN=C(N1)NC2=C(C=C(C=C2Cl)N)Cl
|
|||
| InChI |
1S/C9H10Cl2N4/c10-6-3-5(12)4-7(11)8(6)15-9-13-1-2-14-9/h3-4H,1-2,12H2,(H2,13,14,15)
|
|||
| InChIKey |
IEJXVRYNEISIKR-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 66711-21-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9870, 4268796, 7548410, 7978720, 8151504, 11110712, 14749680, 16363243, 24277751, 29221392, 46505614, 47440415, 47795315, 48169688, 48394205, 50065037, 50110931, 50752782, 51091792, 57321207, 81065531, 85209409, 85220231, 87351876, 90341674, 92711902, 103189137, 103932510, 104299946, 124749396, 124879093, 126630414, 126685318, 128156002, 131342500, 134337550, 135027520, 137001372, 142472722, 160964303, 162178725, 163414818, 163849267, 164788058, 172875570, 175266986, 178103694, 179116563, 179150892, 184533033
|
|||
| ChEBI ID |
CHEBI:2788
|
|||
| ADReCS Drug ID | BADD_D00154 ; BADD_D00155 | |||
| SuperDrug ATC ID |
S01EA03
|
|||
| SuperDrug CAS ID |
cas=066711215
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor Alpha-2 (ADRA2) | Target Info | Agonist | [3], [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7117). | |||
| REF 2 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||
| REF 3 | Apraclonidine attenuates the increases in spinal excitatory amino acid release in rats with adjuvant-induced inflammation. Anesth Analg. 2002 Mar;94(3):701-5; table of contents. | |||
| REF 4 | Topically applied clonidine protects the rat retina from ischaemia/reperfusion by stimulating alpha(2)-adrenoceptors and not by an action on imidazoline receptors. Brain Res. 2001 Jun 15;904(1):126-36. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.